Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
Chronic Obstructive Pulmonary Disease (COPD), COPD, GW642444
Brief summary
This study will assess the safety and efficacy of 5 doses GW642444 in subjects with Chonic Obstructive Pulmonary Disease (COPD)
Interventions
DRUGGW642444 6.25
GW642444 6.25
DRUGGW642444 3mcg
once daily
DRUGGW642444 12.5mcg
GW642444 12.5mcg
DRUGGW642444 25mcg
GW642444 25mcg
DRUGGW642444 50mcg
GW642444 50mcg
OTHERplacebo
placebo
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Subjects eligible for enrollment in the study must meet all of the following criteria: * Informed Consent: Subjects who give their signed written informed consent to participate. * Gender: Male or females who are 40 - 80 years of age at Visit 1. A female is eligible to enter and participate in the study if she is of: * Non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal); or * Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly (i.e. in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to follow-up contact): * Complete abstinence from intercourse from screening until 2 weeks after the follow-up contact; or * Male partner is sterile (vasectomy with documentation of azoospermia) prior to female subject entry into the study, and this male partner is the sole partner for that subject; or * Implants of levonorgestrel inserted for at least 1 month prior to the study medication administration but not beyond the third successive year following insertion; or * Injectable progestogen administered for at least 1 month prior to study medication administration and administered for 1 month following study completion; or * Oral contraceptive (combined or progestogen only) administered for at least one monthly cycle prior to study medication administration; or * Double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository); or * An intrauterine device (IUD), inserted by a qualified physician, with published data showing that the highest expected failure rate is less than 1% per year; or * Estrogenic vaginal ring; or * Percutaneous contraceptive patches * COPD Diagnosis: Subjects with an established clinical history of COPD in accordance with the following definition by the American Thoracic Society/European Respiratory Society \[Celli, 2004\]: COPD is a preventable and treatable disease characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it also produces significant systemic consequences. * Tobacco Use: Must have current or prior history of at least 10 pack-years of cigarette smoking. \[number of pack years = (number of cigarettes per day / 20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years\]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1. * Severity of Disease: * Subjects with a measured post-salbutamol FEV1/FVC ratio of ≤0.70 at Visit 1 (Screening). * Subjects with a measured post-salbutamol FEV1 ≥35 and ≤70% of predicted normal values calculated using NHANES III reference equations at Visit 1 (Screening).
Exclusion criteria
Subjects meeting any of the following criteria must not be enrolled in the study: * Pregnancy: Women who are pregnant or lactating. * Asthma: Subjects with a primary diagnosis of asthma. (Subjects with a prior history of asthma are eligible if COPD is currently their primary diagnosis) * a1-antitrypsin deficiency: Subjects with a1-antitrypsin deficiency as the underlying cause of COPD. * Other Respiratory disorders: Subjects with active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung disease or other active pulmonary disease. * Lung Resection: Subjects with lung volume reduction surgery within the previous 12 months. * Chest X-ray: Chest X-ray (or CT scan) reveals evidence of clinically significant abnormalities not believed to be due to the presence of COPD. A chest x-ray must be taken if a chest x-ray or CT scan is not available within the 6 months preceding the Screening Visit. For sites in Germany, if a chest x-ray (or CT scan) is not available in the 6 months preceding the Screening (Visit 1), the subject will not be eligible for the study. * Hospitalization: Subjects who are hospitalized due to poorly controlled COPD within 12 weeks of the screening visit. * Poorly controlled COPD: Subjects with poorly controlled COPD, defined as the occurrence of any of the following in the 6 weeks prior to Visit 1: * acute worsening of COPD that is managed by subject with corticosteroids or antibiotics, or * acute worsening of COPD that requires treatment prescribed by a physician * Other Diseases/Abnormalities: Subjects with clinically significant cardiovascular neurological, psychiatric, renal, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. * Lower Respiratory Tract Infection: Subjects with lower respiratory tract infections which required the use of antibiotics within 6 weeks prior to visit 1. * 12-Lead ECG: An abnormal and clinically significant 12-lead electrocardiogram (ECG) that results in an active medical problem. For the purposes of this study, an abnormal ECG is defined as a 12-lead tracing which is interpreted with (but not limited to) any of the following: * Clinically significant conduction abnormalities (e.g., left bundle branch block, Wolff-Parkinson-White syndrome) * Clinically significant arrhythmias (e.g., atrial fibrillation, ventricular tachycardia) The investigator will determine the clinical significance of any ECG abnormality and determine if a subject is precluded from entering the study. However, the following predetermined ECG abnormalities are considered clinically significant and will result in exclusion of a subject: * A mean QTc(B) value at screening \>450msec, or uncorrected QT\>600msec or an ECG that is not suitable for QT measurements (e.g. poorly defined termination of the T wave) * Ventricular rate \< 45 beats per minute. * PR interval \> 240msec. * Evidence of second or third degree atrioventricular (AV) block * Pathological Q waves * Non-specific intraventricular conduction delay * ST-T wave abnormalities (excluding non-specific ST-T wave abnormalities) * Right or left complete bundle branch block * Hypertension: Subjects with clinically significant hypertension that is uncontrolled. * Hepatitis: Subjects with a positive Hepatitis B surface antigen or positive hepatitis C antibody pre-study or at Screening. * Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma would not be excluded if the subject was considered cured in less than 5 years since diagnosis. * Drug allergy: Subjects with a history of hypersensitivity to any beta-agonist or any component of the MDI and/or nebule or sensitivity to any of the constituents of the dry powder product (magnesium stearate or lactose). In addition patients with a history of severe milk protein allergy would also be excluded. * Drug abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years. * Medication prior to spirometry: Subjects who are medically unable to withhold their salbutamol for the 6 hour period required prior to spirometry testing at each study visit would be ineligible for the study. * Additional Medications: The following medications are not permitted during this study and must not have been taken for the indicated times prior to Visit 1 (See Prohibited Medications): Medication (Required period of time prior to screening visit): * Ipratropium or ipratropium/salbutamol combination product (6 hours) * Inhaled short acting beta-agonists (study salbutamol will be provided)(6 hours) * Oral beta2-agonists (48 hours) * LABAs (salmeterol and formoterol)(48 hours) * Corticosteroids/Long acting beta-agonist combination products (48 hours for the LABA component) * Theophylline preparations (48 hours) * Cromolyn and nedocromil inhalers(24 hours) * Zafirlukast, montelukast, zileuton(48 hours) * Tiotropium (1 Week) * Depot corticosteroids (12 Weeks) * Intra-articular corticosteroids (24 hours) * Inhaled corticosteroids\>1000mcg/day of fluticasone propionate or equivalent (4 Weeks) * Any other investigational medication (30 days or within 5 drug half-lives of the investigational drug (whichever is longer)) * P-glycoprotein inhibitors (e.g., ritonavir, ketoconazole) or Cytochrome P 3A4 inhibitors (e.g., cimetidine) (4 weeks (grapefruit is allowed up to the screening visit)) * Other Medications: Subjects receiving treatment with tricyclic antidepressants, MAOs, beta-adrenergic antagonists, anticonvulsants (barbiturates, hydantoins, and carbamazepine) or phenothiazines would be ineligible for the study. * Oxygen: Subjects receiving long-term-oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen prn use is not exclusionary. * Sleep apnea: Subjects with clinically significant sleep apnea that is uncontrolled. * Pulmonary Rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Visit 1 (Screening) or who will enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation program are not excluded. * Non-compliance: Subjects unable to comply with study procedures. * Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participation in this study. * Questionable validity of Consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation, substance abuse, (including drug and alcohol), or other conditions, which will limit the validity of informed consent to participate in the study. * Prior use of Study Medication: Subjects who have received the investigational drug GW642444 in previous studies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change From Baseline in Trough (Pre Bronchodilator and Pre Dose) FEV1 on Day 29 | Baseline (BL) and Day 29 | Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcibly exhaled from the lungs in one second. Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. If one of these two assessments was missing then Baseline is defined as the single pre-dose FEV1 value at Day 1. The trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24-hours after dosing on Day 28 and the Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. Change from Baseline in trough FEV1 was calculated as the value on Day 29 minus the value at Baseline. Analysis was performed using Analysis of Covariance (ANCOVA) using Last Observation Carried Forward (LOCF) with covariates of baseline, sex, age, smoking status (at screening), reversibility stratum, and treatment (trt). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Baseline to Day 28 | Weighted mean was derived by calculating the AUC, and then dividing by the relevant time interval. The weighted mean change from Baseline was calculated as the weighted mean of the 24 hour serial FEV1 measures on Day 1 and Day 28 minus the Baseline value. Serial FEV1 measurements were taken on Day 1 and Day 28 (post-dose FEV1 after 5, 15, 30 minutes and 1, 2, 4, 8, 12, 23 and 24 hours). AUC was calculated only when there was at least 3 non-missing values between 0 and 24 hours and must have a value at 23 or 24 hours. Analysis performed used a repeated measures model with covariates of treatment, baseline, sex, age, smoking status (at Screening), reversibility stratum, Day (nominal), day by Baseline, and day by treatment interactions. |
| Time to >= 12% Increase From Baseline in FEV1 (0-4 Hours Post-dose) | Baseline and Day 1 | Forced expiratory volume in one second (FEV1) is a measure of lung function defined as the maximal amount of air that can be forcibly exhaled from the lungs in one second. Time until participants achieved a \>=12% increase from Baseline FEV1 (0-4 hours post-dose) are presented. Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. If one of these two assessments was missing then Baseline is defined as the single pre-dose FEV1 on Day 1.Time to \>= 12% increase from Baseline (on Day 1) is defined as the time when the first post-dose FEV1 (on Day 1) is \>=12% above Baseline FEV1. Time to \>= 12% increase from Baseline was assessed over the 0-4 hour time period and only used lung function data recorded up to 6 hours post the Day 1 dose. |
| Time to >= 100 Milliliter (mL) Increase From Baseline in FEV1 (0-4 Hours Post-dose) | Baseline and Day 1 | Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcibly exhaled from the lungs in one second. Time until participants achieve \>=100 mL increase from Baseline FEV1 (0-4 hours post-dose) are presented. Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. Time to \>= 100mL increase from Baseline (on Day 1) is defined as the time until the first post-dose FEV1 (on Day 1) is \>= 100mL above Baseline FEV1. Time to \>= 100mL increase from Baseline (on Day 1) was calculated only if there was at least one non-missing FEV1 value recorded within the first hour of dosing. Time to \>= 100mL increase from Baseline was assessed over the 0-4 time period and only used lung function data recorded up to 6 hours post the Day 1 dose. Participants who did not achieve \>= 100mL increase from Baseline over this time period were censored. |
Countries
Argentina, Canada, Chile, Denmark, Estonia, Germany, Mexico, Peru, Philippines, Poland, Russia, Slovakia, South Korea, United States
Participant flow
Pre-assignment details
At Visit (V) 1, eligible participants (par.) entered a 2-week, single-blind placebo Run-in Period (RIP) to establish a stable Baseline. At V 2, eligible par. were randomized to a 28 day, double-blind Treatment Period. 1206 par. were screened, 851 par. entered the RIP and 605 par. were randomized, out of which 602 par. received \>=1 treatment dose.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received placebo (1 actuation) OD in the morning from the novel dual strip dry powder inhaler for 28 days. In addition, participants were provided supplemental salbutamol (MDI and/or nebules) inhalation to be used as needed throughout the study. | 101 |
| GW642444M 3 µg OD Participants received GW642444M 3 µg (one actuation) OD in the morning from the novel dual strip dry powder inhaler for 28 days. In addition, participants were provided supplemental salbutamol (MDI and/or nebules) inhalation to be used as needed throughout the study. | 99 |
| GW642444M 6.25 µg OD Participants received GW642444M 6.25 µg (one actuation) OD in the morning from the novel dual strip dry powder inhaler for 28 days. In addition, participants were provided supplemental salbutamol (MDI and/or nebules) inhalation to be used as needed throughout the study. | 101 |
| GW642444M 12.5 µg OD Participants received GW642444M 12.5 µg (one actuation) OD in the morning from the novel dual strip dry powder inhaler for 28 days. In addition, participants were provided supplemental salbutamol (MDI and/or nebules) inhalation to be used as needed throughout the study. | 101 |
| GW642444M 25 µg OD Participants received GW642444M 25 µg (one actuation) OD in the morning from the novel dual strip dry powder inhaler for 28 days. In addition, participants were provided supplemental salbutamol (MDI and/or nebules) inhalation to be used as needed throughout the study. | 101 |
| GW642444M 50 µg OD Participants received GW642444M 50 µg (one actuation) OD in the morning from the novel dual strip dry powder inhaler for 28 days. In addition, participants were provided supplemental salbutamol (MDI and/or nebules) inhalation to be used as needed throughout the study. | 99 |
| Total | 602 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 |
|---|---|---|---|---|---|---|---|---|
| 2-week Single-Blind Run-in Period | Adverse Event | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-week Single-Blind Run-in Period | Did Not Meet Continuation Criteria | 173 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-week Single-Blind Run-in Period | Lost to Follow-up | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-week Single-Blind Run-in Period | Physician Decision | 18 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-week Single-Blind Run-in Period | Received Study Medication in Error | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-week Single-Blind Run-in Period | Study Closed/Terminated | 32 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-week Single-Blind Run-in Period | Withdrawal by Subject | 15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Double-Blind Treatment Period | Adverse Event | 0 | 3 | 2 | 4 | 2 | 0 | 1 |
| Double-Blind Treatment Period | Lack of Efficacy | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| Double-Blind Treatment Period | Met Protocol Defined Stopping Criteria | 0 | 1 | 2 | 1 | 2 | 3 | 1 |
| Double-Blind Treatment Period | Physician Decision | 0 | 5 | 1 | 0 | 3 | 1 | 2 |
| Double-Blind Treatment Period | Protocol Violation | 0 | 5 | 5 | 3 | 0 | 3 | 4 |
| Double-Blind Treatment Period | Withdrawal by Subject | 0 | 1 | 1 | 2 | 1 | 2 | 0 |
Baseline characteristics
| Characteristic | Total | GW642444M 3 µg OD | GW642444M 6.25 µg OD | Placebo | GW642444M 12.5 µg OD | GW642444M 25 µg OD | GW642444M 50 µg OD |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 61.9 Years STANDARD_DEVIATION 8.34 | 61.1 Years STANDARD_DEVIATION 8.57 | 62.0 Years STANDARD_DEVIATION 7.94 | 61.6 Years STANDARD_DEVIATION 8.53 | 62.6 Years STANDARD_DEVIATION 8.03 | 62.6 Years STANDARD_DEVIATION 8.88 | 61.4 Years STANDARD_DEVIATION 8.12 |
| Gender Female | 232 Participants | 31 Participants | 37 Participants | 44 Participants | 44 Participants | 42 Participants | 34 Participants |
| Gender Male | 370 Participants | 68 Participants | 64 Participants | 57 Participants | 57 Participants | 59 Participants | 65 Participants |
| Race/Ethnicity, Customized African American/African Heritage (HER) | 16 Participants | 1 Participants | 3 Participants | 3 Participants | 2 Participants | 4 Participants | 3 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native | 11 Participants | 2 Participants | 0 Participants | 0 Participants | 4 Participants | 2 Participants | 3 Participants |
| Race/Ethnicity, Customized American Indian or Alaska Native & White | 4 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Central/South Asian HER | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Japanese/East Asian HER/South East Asian HER | 55 Participants | 11 Participants | 13 Participants | 7 Participants | 8 Participants | 10 Participants | 6 Participants |
| Race/Ethnicity, Customized White | 515 Participants | 84 Participants | 84 Participants | 90 Participants | 86 Participants | 84 Participants | 87 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 15 / 101 | 9 / 99 | 14 / 101 | 5 / 101 | 5 / 101 | 10 / 99 |
| serious Total, serious adverse events | 0 / 101 | 1 / 99 | 1 / 101 | 2 / 101 | 0 / 101 | 0 / 99 |
Outcome results
Primary
Mean Change From Baseline in Trough (Pre Bronchodilator and Pre Dose) FEV1 on Day 29
Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcibly exhaled from the lungs in one second. Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. If one of these two assessments was missing then Baseline is defined as the single pre-dose FEV1 value at Day 1. The trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24-hours after dosing on Day 28 and the Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. Change from Baseline in trough FEV1 was calculated as the value on Day 29 minus the value at Baseline. Analysis was performed using Analysis of Covariance (ANCOVA) using Last Observation Carried Forward (LOCF) with covariates of baseline, sex, age, smoking status (at screening), reversibility stratum, and treatment (trt).
Time frame: Baseline (BL) and Day 29
Population: Intent-to-Treat (ITT) Population: all participants who were randomized to trt and received \>= 1 dose of study medication. When the endpoint was missing, the last valid non-missing on-trt, post-BL trough assessment was used instead. Only those participants available at the specified time points without missing covariate information were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Mean Change From Baseline in Trough (Pre Bronchodilator and Pre Dose) FEV1 on Day 29 | 0.029 Liters | Standard Error 0.0188 |
| GW642444M 3 µg OD | Mean Change From Baseline in Trough (Pre Bronchodilator and Pre Dose) FEV1 on Day 29 | 0.120 Liters | Standard Error 0.019 |
| GW642444M 6.25 µg OD | Mean Change From Baseline in Trough (Pre Bronchodilator and Pre Dose) FEV1 on Day 29 | 0.127 Liters | Standard Error 0.0188 |
| GW642444M 12.5 µg OD | Mean Change From Baseline in Trough (Pre Bronchodilator and Pre Dose) FEV1 on Day 29 | 0.138 Liters | Standard Error 0.019 |
| GW642444M 25 µg OD | Mean Change From Baseline in Trough (Pre Bronchodilator and Pre Dose) FEV1 on Day 29 | 0.166 Liters | Standard Error 0.019 |
| GW642444M 50 µg OD | Mean Change From Baseline in Trough (Pre Bronchodilator and Pre Dose) FEV1 on Day 29 | 0.194 Liters | Standard Error 0.019 |
p-value: <0.00195% CI: [0.039, 0.144]ANCOVA
p-value: <0.00195% CI: [0.046, 0.15]ANCOVA
p-value: <0.00195% CI: [0.057, 0.162]ANCOVA
p-value: <0.00195% CI: [0.085, 0.19]ANCOVA
p-value: <0.00195% CI: [0.112, 0.217]ANCOVA
Secondary
Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28
Weighted mean was derived by calculating the AUC, and then dividing by the relevant time interval. The weighted mean change from Baseline was calculated as the weighted mean of the 24 hour serial FEV1 measures on Day 1 and Day 28 minus the Baseline value. Serial FEV1 measurements were taken on Day 1 and Day 28 (post-dose FEV1 after 5, 15, 30 minutes and 1, 2, 4, 8, 12, 23 and 24 hours). AUC was calculated only when there was at least 3 non-missing values between 0 and 24 hours and must have a value at 23 or 24 hours. Analysis performed used a repeated measures model with covariates of treatment, baseline, sex, age, smoking status (at Screening), reversibility stratum, Day (nominal), day by Baseline, and day by treatment interactions.
Time frame: Baseline to Day 28
Population: ITT Population. The number of participants presented represents those with data available at either of time points being presented. The numbers given in the category titles represent the number of participants with data available at the time point given.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 1, n=100, 97, 100, 99 | 0.028 Liters | Standard Error 0.0135 |
| Placebo | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 28, n=84, 88, 91, 92 | 0.010 Liters | Standard Error 0.0189 |
| GW642444M 3 µg OD | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 1, n=100, 97, 100, 99 | 0.085 Liters | Standard Error 0.0137 |
| GW642444M 3 µg OD | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 28, n=84, 88, 91, 92 | 0.114 Liters | Standard Error 0.0187 |
| GW642444M 6.25 µg OD | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 1, n=100, 97, 100, 99 | 0.132 Liters | Standard Error 0.0135 |
| GW642444M 6.25 µg OD | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 28, n=84, 88, 91, 92 | 0.135 Liters | Standard Error 0.0185 |
| GW642444M 12.5 µg OD | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 1, n=100, 97, 100, 99 | 0.149 Liters | Standard Error 0.0136 |
| GW642444M 12.5 µg OD | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 28, n=84, 88, 91, 92 | 0.152 Liters | Standard Error 0.0185 |
| GW642444M 25 µg OD | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 1, n=100, 97, 100, 99 | 0.178 Liters | Standard Error 0.0136 |
| GW642444M 25 µg OD | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 28, n=84, 88, 91, 92 | 0.168 Liters | Standard Error 0.0185 |
| GW642444M 50 µg OD | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 1, n=100, 97, 100, 99 | 0.202 Liters | Standard Error 0.0137 |
| GW642444M 50 µg OD | Time-adjusted Area Under the Curve (AUC) (i.e. Weighted Mean Change From Baseline) for 24 Hour Serial FEV1 on Days 1 and 28 | Day 28, n=84, 88, 91, 92 | 0.186 Liters | Standard Error 0.0186 |
Secondary
Time to >= 100 Milliliter (mL) Increase From Baseline in FEV1 (0-4 Hours Post-dose)
Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcibly exhaled from the lungs in one second. Time until participants achieve \>=100 mL increase from Baseline FEV1 (0-4 hours post-dose) are presented. Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. Time to \>= 100mL increase from Baseline (on Day 1) is defined as the time until the first post-dose FEV1 (on Day 1) is \>= 100mL above Baseline FEV1. Time to \>= 100mL increase from Baseline (on Day 1) was calculated only if there was at least one non-missing FEV1 value recorded within the first hour of dosing. Time to \>= 100mL increase from Baseline was assessed over the 0-4 time period and only used lung function data recorded up to 6 hours post the Day 1 dose. Participants who did not achieve \>= 100mL increase from Baseline over this time period were censored.
Time frame: Baseline and Day 1
Population: ITT Population. Only participants available at the indicated time points were assessed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to >= 100 Milliliter (mL) Increase From Baseline in FEV1 (0-4 Hours Post-dose) | NA Minutes |
| GW642444M 3 µg OD | Time to >= 100 Milliliter (mL) Increase From Baseline in FEV1 (0-4 Hours Post-dose) | 32 Minutes |
| GW642444M 6.25 µg OD | Time to >= 100 Milliliter (mL) Increase From Baseline in FEV1 (0-4 Hours Post-dose) | 16 Minutes |
| GW642444M 12.5 µg OD | Time to >= 100 Milliliter (mL) Increase From Baseline in FEV1 (0-4 Hours Post-dose) | 16 Minutes |
| GW642444M 25 µg OD | Time to >= 100 Milliliter (mL) Increase From Baseline in FEV1 (0-4 Hours Post-dose) | 6 Minutes |
| GW642444M 50 µg OD | Time to >= 100 Milliliter (mL) Increase From Baseline in FEV1 (0-4 Hours Post-dose) | 6 Minutes |
Secondary
Time to >= 12% Increase From Baseline in FEV1 (0-4 Hours Post-dose)
Forced expiratory volume in one second (FEV1) is a measure of lung function defined as the maximal amount of air that can be forcibly exhaled from the lungs in one second. Time until participants achieved a \>=12% increase from Baseline FEV1 (0-4 hours post-dose) are presented. Baseline FEV1 is defined as the mean of the two assessments made 30 minutes pre-dose and immediately pre-dose on Day 1. If one of these two assessments was missing then Baseline is defined as the single pre-dose FEV1 on Day 1.Time to \>= 12% increase from Baseline (on Day 1) is defined as the time when the first post-dose FEV1 (on Day 1) is \>=12% above Baseline FEV1. Time to \>= 12% increase from Baseline was assessed over the 0-4 hour time period and only used lung function data recorded up to 6 hours post the Day 1 dose.
Time frame: Baseline and Day 1
Population: ITT Population. Only participants available at the indicated time points were assessed.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Placebo | Time to >= 12% Increase From Baseline in FEV1 (0-4 Hours Post-dose) | NA Minutes |
| GW642444M 3 µg OD | Time to >= 12% Increase From Baseline in FEV1 (0-4 Hours Post-dose) | 120 Minutes |
| GW642444M 6.25 µg OD | Time to >= 12% Increase From Baseline in FEV1 (0-4 Hours Post-dose) | 30 Minutes |
| GW642444M 12.5 µg OD | Time to >= 12% Increase From Baseline in FEV1 (0-4 Hours Post-dose) | 30 Minutes |
| GW642444M 25 µg OD | Time to >= 12% Increase From Baseline in FEV1 (0-4 Hours Post-dose) | 18 Minutes |
| GW642444M 50 µg OD | Time to >= 12% Increase From Baseline in FEV1 (0-4 Hours Post-dose) | 16 Minutes |